BioArctic AB (publ) (STO:BIOA.B)
Sweden
· Delayed Price · Currency is SEK 174.10
-2.10 (-1.19%)
May 13, 2025, 4:03 PM CET
BioArctic AB Revenue
In the year 2024, BioArctic AB had annual revenue of 257.35M SEK, down -58.22%. BioArctic AB had revenue of 101.24M in the quarter ending December 31, 2024, with 818.24% growth.
Revenue
257.35M
Revenue Growth
-58.22%
P/S Ratio
59.17
Revenue / Employee
2.41M
Employees
107
Market Cap
15.23B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 257.35M | -358.64M | -58.22% |
| Dec 31, 2023 | 616.00M | 386.56M | 168.49% |
| Dec 31, 2022 | 229.43M | 203.77M | 794.02% |
| Dec 31, 2021 | 25.66M | -39.54M | -60.64% |
| Dec 31, 2020 | 65.21M | -217.74M | -76.95% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Swedish Orphan Biovitrum AB | 26.24B |
| Sectra AB | 3.30B |
| Getinge AB | 35.57B |
| Camurus AB | 1.87B |
| Medicover AB | 23.56B |
| AddLife AB | 10.42B |
| Vitrolife AB | 3.61B |
| Vimian Group AB | 4.24B |
BioArctic AB News
- 15 hours ago - Invitation to presentation of BioArctic's first quarter report for January - March 2025 on May 21 at 9.30 a.m. CET - PRNewsWire
- 5 days ago - Exidavnemab phase 2a study expanded to include MSA patients - PRNewsWire
- 6 weeks ago - The European Commission refers lecanemab decision to Appeal Committee - PRNewsWire
- 7 weeks ago - BioArctic's partner Eisai presents sales simulation for Leqembi® at its annual press conference - PRNewsWire
- 2 months ago - BioArctic receives Orphan Drug Designation for exidavnemab the US - PRNewsWire
- 2 months ago - Therapeutic Goods Administration decides not to register lecanemab in Australia - PRNewsWire
- 2 months ago - The Committee for Medicinal Products for Human Use (CHMP) reaffirms positive opinion for Lecanemab in early Alzheimer's disease in the EU - PRNewsWire
- 3 months ago - Leqembi® sales reaches €200 million - first sales milestone achieved - PRNewsWire